SEATTLE–(BUSINESS WIRE)–Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has been named by Fierce Medtech as one of 2021’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
Tasso’s signature blood collection products and services are currently in use worldwide for a variety of healthcare, pharma, and research applications. The simple, patient-centric technology enables convenient remote collection of clinical grade blood, eliminating clinic access challenges. The combination of Tasso’s innovative, virtually painless blood collection technology with an integrated logistics platform empowers pharmaceutical companies, academic institutions, and payers to expand their home health operations.
“The COVID-19 pandemic has led to a fundamental shift in how we think about healthcare, and demand for patient-centric, in-home solutions is greater than ever,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “To be recognized as one of the 2021 Fierce 15 Med Tech Companies is a tremendous honor and another strong validation of our team and technology. We will continue to build on this momentum and enable more people worldwide to benefit from streamlined access to clinical diagnostics.”